Davide Melisi (D Melisi)

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 31

Top Venues

Journal of personalized medicine

Therapeutic advances in medical oncology

Cancers

Antioxidants (Basel, Switzerland)

Universita degli Studi di Verona

Universita degli Studi di Napoli Federico II (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Universita degli Studi di Verona Dec 01 2011

Italy

Assistant Professor of Medical Oncology :: Medicine

Istituto Nazionale Tumori IRCCS Fondazione Pascale

Italy

Clinical and Experimental Tenure Lecturer

University of Texas MD Anderson Cancer Center Department of Gastrointestinal Medical Oncology

United States

Postdoctoral Fellow

Education History

Universita degli Studi di Napoli Federico II

Italy

PHD

Publications

Serge Cedrick Toya Mbiandjeu, Angela Siciliano, Alessandro Mattè, Enrica Federti, Massimiliano Perduca, Davide Melisi, Immacolata Andolfo, Angela Amoresano, Achille Iolascon, Maria Teresa Valenti, Francesco Turrini, Michele Bovi, Arianna Pisani, Antonio Recchiuti, Domenico Mattoscio, Veronica Riccardi, Luca Giuseppe Dalle Carbonare, Carlo Brugnara, Narla Mohandas, Lucia De Franceschi
Nrf2 Plays a Key Role in Erythropoiesis during Aging. Antioxidants (Basel, Switzerland) 13 (4) (2024)
Davide Melisi, Simona Casalino, Silvia Pietrobono, Alberto Quinzii, Camilla Zecchetto, Valeria Merz
Integration of liposomal irinotecan in the first-line treatment of metastatic pancreatic cancer: try to do not think about the white bear. Therapeutic advances in medical oncology 16 (2024)
Davide Melisi, Simona Casalino, Silvia Pietrobono, Alberto Quinzii, Camilla Zecchetto, Valeria Merz
Integration of liposomal irinotecan in the first-line treatment of metastatic pancreatic cancer: try to do not think about the white bear. Therapeutic advances in medical oncology 16 (2024)
Serge Cedrick Toya Mbiandjeu, Angela Siciliano, Alessandro Mattè, Enrica Federti, Massimiliano Perduca, Davide Melisi, Immacolata Andolfo, Angela Amoresano, Achille Iolascon, Maria Teresa Valenti, Francesco Turrini, Michele Bovi, Arianna Pisani, Antonio Recchiuti, Domenico Mattoscio, Veronica Riccardi, Luca Giuseppe Dalle Carbonare, Carlo Brugnara, Narla Mohandas, Lucia De Franceschi
Nrf2 Plays a Key Role in Erythropoiesis during Aging. Antioxidants (Basel, Switzerland) 13 (4) (2024)
Maria Bencivenga, Lorena Torroni, Mariagiulia Dal Cero, Alberto Quinzii, Camilla Zecchetto, Valeria Merz, Simona Casalino, Francesco Taus, Silvia Pietrobono, Domenico Mangiameli, Federica Filippini, Mariella Alloggio, Claudia Castelli, Mar Iglesias, Manuel Pera, Davide Melisi
YAP Activation Is Associated with a Worse Prognosis of Poorly Cohesive Gastric Cancer. Journal of personalized medicine 13 (9) (2023)
Camilla Zecchetto, Alberto Quinzii, Simona Casalino, Marina Gaule, Camilla Pesoni, Valeria Merz, Silvia Pietrobono, Domenico Mangiameli, Martina Pasquato, Stefano Milleri, Simone Giacopuzzi, Maria Bencivenga, Anna Tomezzoli, Giovanni de Manzoni, Davide Melisi
Targeting FGFR Pathway Is Not an Effective Therapeutic Strategy in Patients with Unselected Metastatic Esophagogastric Cancer Resistant to Trastuzumab. Journal of personalized medicine 13 (3) (2023)
Camilla Zecchetto, Alberto Quinzii, Simona Casalino, Marina Gaule, Camilla Pesoni, Valeria Merz, Silvia Pietrobono, Domenico Mangiameli, Martina Pasquato, Stefano Milleri, Simone Giacopuzzi, Maria Bencivenga, Anna Tomezzoli, Giovanni de Manzoni, Davide Melisi
Targeting FGFR Pathway Is Not an Effective Therapeutic Strategy in Patients with Unselected Metastatic Esophagogastric Cancer Resistant to Trastuzumab. Journal of personalized medicine 13 (3) (2023)
Simone Augustinus, Hanneke W M van Laarhoven, Geert A Cirkel, Jan Willem B de Groot, Bas Groot Koerkamp, Teresa Macarulla, Davide Melisi, Eileen M O'Reilly, Hjalmar C van Santvoort, Tara M Mackay, Marc G Besselink, Johanna W Wilmink, null null
Timing of Initiation of Palliative Chemotherapy in Asymptomatic Patients with Metastatic Pancreatic Cancer: An International Expert Survey and Case-Vignette Study. Cancers 15 (23) (2023)
Camilla Zecchetto, Alberto Quinzii, Simona Casalino, Marina Gaule, Camilla Pesoni, Valeria Merz, Silvia Pietrobono, Domenico Mangiameli, Martina Pasquato, Stefano Milleri, Simone Giacopuzzi, Maria Bencivenga, Anna Tomezzoli, Giovanni de Manzoni, Davide Melisi
Targeting FGFR Pathway Is Not an Effective Therapeutic Strategy in Patients with Unselected Metastatic Esophagogastric Cancer Resistant to Trastuzumab. Journal of personalized medicine 13 (3) (2023)
Silvia Pietrobono, Fabio Sabbadini, Monica Bertolini, Domenico Mangiameli, Veronica De Vita, Federica Fazzini, Giulia Lunardi, Simona Casalino, Enza Scarlato, Valeria Merz, Camilla Zecchetto, Alberto Quinzii, Giusy Di Conza, Michael Lahn, Davide Melisi
Autotaxin secretion is a stromal mechanism of adaptive resistance to TGFβ inhibition in pancreatic ductal adenocarcinoma. Cancer research (2023)
Alessandro Rizzo, Massimiliano Salati, Giorgio Frega, Valeria Merz, Francesco Caputo, Alessandro Di Federico, Andrea Palloni, Riccardo Carloni, Angela Dalia Ricci, Gennaro Gadaleta-Caldarola, Carlo Messina, Andrea Spallanzani, Fabio Gelsomino, Stefania Benatti, Gabriele Luppi, Davide Melisi, Massimo Dominici, Giovanni Brandi
Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study. Medicina (Kaunas, Lithuania) 58 (11) (2022)
Marina Gaule, Camilla Pesoni, Alberto Quinzii, Camilla Zecchetto, Simona Casalino, Valeria Merz, Serena Contarelli, Silvia Pietrobono, Elena Vissio, Luca Molinaro, Enrica Manzin, Roberta Volpatto, Giorgio Vellani, Davide Melisi
Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion. JCO precision oncology 6 (2022)
Davide Melisi, Do-Youn Oh, Antoine Hollebecque, Emiliano Calvo, Anna Varghese, Erkut Borazanci, Teresa Macarulla, Valeria Merz, Camilla Zecchetto, Yumin Zhao, Ivelina Gueorguieva, Michael Man, Leena Gandhi, Shawn T Estrem, Karim A Benhadji, Mark C Lanasa, Emin Avsar, Susan C Guba, Rocio Garcia-Carbonero
Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. Journal for immunotherapy of cancer 9 (3) (2021)
Alfredo Carrato, Davide Melisi, Gerald Prager, Christoph B Westphalen, Anabel Ferreras, Nathalie D'Esquermes, Julien Taieb, Teresa M Mercadé
Chart review of diagnostic methods, baseline characteristics and symptoms for European patients with pancreatic cancer. Future oncology (London, England) 17 (15) (2021)
Fabio Sabbadini, Monica Bertolini, Serena De Matteis, Domenico Mangiameli, Serena Contarelli, Silvia Pietrobono, Davide Melisi
The Multifaceted Role of TGF-β in Gastrointestinal Tumors. Cancers 13 (16) (2021)
Timothy Anthony Yap, Maria Vieito, Capucine Baldini, Juan Manuel Sepúlveda-Sánchez, Shunsuke Kondo, Matteo Simonelli, Rasha Cosman, Andre van der Westhuizen, Victoria Atkinson, Antoine F Carpentier, Mario Löhr, Rebecca Redman, Warren Mason, Andres Cervantes, Emilie Le Rhun, Sebastian Ochsenreither, Louise Warren, Yumin Zhao, Sophie Callies, Shawn T Estrem, Michael Man, Leena Gandhi, Emin Avsar, Davide Melisi
First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Massimiliano Salati, Alessandro Rizzo, Valeria Merz, Carlo Messina, Caputo Francesco, Fabio Gelsomino, Andrea Spallanzani, Angela Dalia Ricci, Andrea Palloni, Giorgio Frega, Stefania De Lorenzo, Pietro Carotenuto, Elisa Pettorelli, Stefania Benatti, Gabriele Luppi, Davide Melisi, Giovanni Brandi, Massimo Dominici
Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study. Expert review of gastroenterology & hepatology (2021)
Francesca Simionato, Camilla Zecchetto, Valeria Merz, Alessandro Cavaliere, Simona Casalino, Marina Gaule, Mirko D'Onofrio, Giuseppe Malleo, Luca Landoni, Alessandro Esposito, Giovanni Marchegiani, Luca Casetti, Massimiliano Tuveri, Salvatore Paiella, Filippo Scopelliti, Alessandro Giardino, Isabella Frigerio, Paolo Regi, Paola Capelli, Stefano Gobbo, Armando Gabbrielli, Laura Bernardoni, Vita Fedele, Irene Rossi, Cristiana Piazzola, Serena Giacomazzi, Martina Pasquato, Morena Gianfortone, Stefano Milleri, Michele Milella, Giovanni Butturini, Roberto Salvia, Claudio Bassi, Davide Melisi
A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. Therapeutic advances in medical oncology 12 (2020)
Ian M Silverman, Antoine Hollebecque, Luc Friboulet, Sherry Owens, Robert C Newton, Huiling Zhen, Luis Féliz, Camilla Zecchetto, Davide Melisi, Timothy C Burn
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib. Cancer discovery 11 (2) (2020)
Valeria Merz, Camilla Zecchetto, Davide Melisi
Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma. Future oncology (London, England) 17 (4) (2020)
Valeria Merz, Camilla Zecchetto, Raffaela Santoro, Francesca Simionato, Fabio Sabbadini, Domenico Mangiameli, Geny Piro, Alessandro Cavaliere, Michela Deiana, Maria Teresa Valenti, Diana Bazan, Vita Fedele, Sara Lonardi, Davide Melisi
Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (17) (2020)
Valeria Merz, Camilla Zecchetto, Francesca Simionato, Alessandro Cavaliere, Simona Casalino, Michele Pavarana, Simone Giacopuzzi, Maria Bencivenga, Anna Tomezzoli, Raffaela Santoro, Vita Fedele, Serena Contarelli, Irene Rossi, Serena Giacomazzi, Martina Pasquato, Cristiana Piazzola, Stefano Milleri, Giovanni de Manzoni, Davide Melisi
A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial. Therapeutic advances in medical oncology 12 (2020)
Serena Contarelli, Vita Fedele, Davide Melisi
HOX Genes Family and Cancer: A Novel Role for Homeobox B9 in the Resistance to Anti-Angiogenic Therapies. Cancers 12 (11) (2020)
Alessandro Cavaliere, Valeria Merz, Simona Casalino, Camilla Zecchetto, Francesca Simionato, Hayley Louise Salt, Serena Contarelli, Raffaela Santoro, Davide Melisi
Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer. Journal of gastric cancer 19 (4) (2019)
Davide Melisi, Rocio Garcia-Carbonero, Teresa Macarulla, Denis Pezet, Gael Deplanque, Martin Fuchs, Jorg Trojan, Mark Kozloff, Francesca Simionato, Ann Cleverly, Claire Smith, Shuaicheng Wang, Michael Man, Kyla E Driscoll, Shawn T Estrem, Michael M F Lahn, Karim A Benhadji, Josep Tabernero
TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer. Cancer chemotherapy and pharmacology 83 (5) (2019)
Raffaela Santoro, Marco Zanotto, Francesca Simionato, Camilla Zecchetto, Valeria Merz, Chiara Cavallini, Geny Piro, Fabio Sabbadini, Federico Boschi, Aldo Scarpa, Davide Melisi
Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer. Molecular cancer therapeutics 19 (1) (2019)
Carla Mottini, Hideo Tomihara, Diego Carrella, Alessia Lamolinara, Manuela Iezzi, Justin K Huang, Carla A Amoreo, Simonetta Buglioni, Isabella Manni, Frederick S Robinson, Rosalba Minelli, Ya'an Kang, Jason B Fleming, Michael P Kim, Christopher A Bristow, Daniela Trisciuoglio, Antonella Iuliano, Donatella Del Bufalo, Diego Di Bernardo, Davide Melisi, Giulio F Draetta, Gennaro Ciliberto, Alessandro Carugo, Luca Cardone
Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma. Cancer research 79 (21) (2019)
Alessandra Fiore, Stefano Ugel, Francesco De Sanctis, Sara Sandri, Giulio Fracasso, Rosalinda Trovato, Silvia Sartoris, Samantha Solito, Susanna Mandruzzato, Fulvia Vascotto, Keli L Hippen, Giada Mondanelli, Ursula Grohmann, Geny Piro, Carmine Carbone, Davide Melisi, Rita T Lawlor, Aldo Scarpa, Alessia Lamolinara, Manuela Iezzi, Angelo Paolo Dei Tos, Silvio Bicciato, Bruce R Blazar, Ugur Sahin, Peter J Murray, Vincenzo Bronte
Induction of immunosuppressive functions and NF-κB by FLIP in monocytes. Nature communications 9 (1) (2018)
Geny Piro, Carmine Carbone, Raffaela Santoro, Giampaolo Tortora, Davide Melisi
Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation. Expert review of molecular diagnostics 18 (4) (2018)
C Carbone, G Piro, N Gaianigo, F Ligorio, R Santoro, V Merz, F Simionato, C Zecchetto, G Falco, G Conti, P T Kamga, M Krampera, Federica Di Nicolantonio, L De Franceschi, A Scarpa, G Tortora, Davide Melisi
Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling. International journal of obesity (2005) 42 (3) (2017)
Roberto Ferrara, Francesca Simionato, Chiara Ciccarese, Elisabetta Grego, Sara Cingarlini, Roberto Iacovelli, Emilio Bria, Giampaolo Tortora, Davide Melisi
The development of PARP as a successful target for cancer therapy. Expert review of anticancer therapy 18 (2) (2017)

Davide Melisi.css-eqlu8i{font-size:small;padding-left:4px;} (D Melisi)

Publication Activity (10 Years)

Top Topics

Top Venues

Davide Melisi (D Melisi)